Difficulties in interpreting HbA1c results

Homa, Katarzyna; Majkowska, Liliana

doi:10.20452/pamw.913

Cited by 13 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, hyperglycemia is often elevated temporarily in cases of severe stress (for example: infections, myocardial infarction, cerebral hemorrhage, and surgery) and the use of certain medications can affect glucose levels . In alternative to glucose levels’ monitoring, various glycated serum protein assays, such as fructosamine, have been used to monitor average glycemia over a period of 2–3 weeks . A 1,5‐anhydroglucitol (1,5‐AG), a monosaccharide known to undergo glomerular filtration in the kidneys and subsequent re‐absorption in renal tubules, has been proposed by FDA as an index of short‐term glycemic control in patients with diabetes .…”

Section: Clinical Biomarkers In Use For Dmmentioning

confidence: 99%

Proteome‐base biomarkers in diabetes mellitus: Progress on biofluids' protein profiling using mass spectrometry

Padrão

Ferreira

Vitorino

et al. 2012

Proteomics Clinical Apps

View full text Add to dashboard Cite

The worldwide number of individuals suffering from diabetes mellitus (DM) has been projected to rise from 171 million in 2000 to 366 million in 2030. Identification of specific biomarkers for prediction and monitoring of DM is needed not only for the adequate screening diagnosis but also to assist the design of interventions to prevent or delay progression of this pathology and its attendant complications. Proteomic methods based on MS hold special promise for the identification of novel biomarkers that might form the foundation for new clinical tests, but to date, their contribution has been somehow unfruitful. Indeed, from more than 300 proteins found differently modulated in body fluids from diabetic patients, approximately 50 were validated with other approaches like ELISA or Western blotting and the clinical trials are being initiated to employ biofluids' proteomics (specifically urinary proteomics) in clinical decision. This review provides an overview of MS-based applications in the identification of potential biomarkers for DM, emphasizing the methodological challenges involved.

show abstract

Section: Clinical Biomarkers In Use For Dmmentioning

confidence: 99%

Proteome‐base biomarkers in diabetes mellitus: Progress on biofluids' protein profiling using mass spectrometry

Padrão

Ferreira

Vitorino

et al. 2012

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…Affinity chromatography is an alternative approach, giving a more accurate result. In a report of two diabetic patients with high levels of Hb F, the results of Hb A 1C by agarose gel electrophoresis were higher than expected ones, but through affinity chromatography method the results were wellmatched with patients' blood glucose levels [11].…”

Section: Discussionmentioning

confidence: 78%

“…Average life span of erythrocytes is about 120 days and hence the amount of accumulated glycosylated Hb in blood may represent the available glucose concentration within the past 3 to 4 months. Existence of such relationship is confirmed by laboratory examinations and has become a basis for estimating mean plasma glucose concentration [11]. 1% change in Hb A 1C content is proportionate to 28 to 34 mg/dl change in blood glucose [12].…”

Section: Introductionmentioning

confidence: 86%

Credibility of measurement of fructosamine and hemoglobin A1C in estimating blood glucose level of diabetic patients with thalassemia major

Kosaryan¹,

Mahdavi²,

Aliasgharian³

et al. 2012

Open J. Hematol.

View full text Add to dashboard Cite

Background and Aim: Patients with thalassemia major are classified in high risk group for diabetes mellitus, and therefore monitoring blood glucose level has a vital importance in these people. As high fetal hemoglobin level in thalassemia patients interferes with measurement of glycosylated hemoglobin (hemoglobin A 1C), fructosamine evaluation as an alternative approach is suggested. Materials and Methods: This descriptive study was carried out on 33 diabetes mellitus patients with betathalassemia (21 female and 12 male cases). The following biochemical measurements were done: blood glucose level through biochemical glucose oxidation method, fructosamine by colorimetry, hemoglobin A 1c by immunoturbidimetry, serum ferritin by chemiluminescence and fetal hemoglobin by HPLC methods. Using SPSS software v18.0, statistical analysis was done and correlation between fructosamine and hemoglobin A 1c (Pearson's correlation) and linear regression were investigated. p<0.05 was considered as statistically significant. Results: In female and male patients, blood glucose levels were 204±103 mg/dL and 224±101 mg/dL (p=0.63), fetal hemoglobin were 9%±7% and 13%±9% (p=0.22); serum ferritin levels were 1744±1534 ng/mL and 3253±1773 ng/mL (p=0.96), respectively. Mean serum fructosamine level was 442±124 mmol/L and glycosylated hemoglobin amount was 8.9%±1.8%. These two parameters showed significant correlation (r=0.69, p<0.01). Blood glucose level with hemoglobin A 1c (r=0.75, p<0.01) and fructosamine (r=0.54, p<0/01) showed a significant correlation. Conclusion: In diabetic patients with thalassemia major who have frequent blood transfusion, evaluation of serum fructosamine and glycosylated hemoglobin levels are both reliable approaches for estimating blood glucose levels and the two methods can be used alternatively.

show abstract

“…La medición de HbA1c se ha utilizado como prueba de seguimiento del control de la DM (28); sin embargo, fue aprobada en el 2010 para diagnóstico de DM cuando se tiene un nivel ≥ 6,5 %, siempre y cuando se utilice una prueba diagnóstica certificada por el National Glycohemoglobin Standardization Program (NGSP), estandarizada con el ensayo de referencia Diabetes Control and Complications Trial (DCCT) (29). La HbA1c no se altera con cambios en la dieta, no amerita ayuno, es estable a temperatura ambiente, y varía poco entre exámenes (30); puede resultar falsamente elevada en caso de uso de salicilatos, diuréticos, hipertrigliceridemia, policitemia y esplenectomía, y falsamente baja en postransfusión, hemodiálisis, anemia hemolítica, uso de VIT "C" y "E" (31,32).…”

Section: Introductionunclassified

Prevalencia de Diabetes Mellitus Gestacional por curva de tolerancia a la glucosa en semanas 24 a 28. Cohorte prospectiva en Armenia Colombia, 2015-2016

Ruiz-Hoyos

Londoño-Franco

Ramírez-Aristizábal³

2018

Rev. Colomb. Obstet. Ginecol.

View full text Add to dashboard Cite

Objetivo: determinar, por curva de tolerancia a la glucosa (CTG), la prevalencia de diabetes mellitus gestacional (DMG) que se inicia en el segundo o tercer trimestre del embarazo, y explorar la relación con resultados del embarazo en gestantes de Armenia.Materiales y métodos: estudio prospectivo en cohorte de gestantes que consultaron a un centro de atención de primer nivel en Armenia, para control prenatal antes de la semana 14 y firmaron el consentimiento informado. Se excluyeron gestantes con hipertensión o diabetes previa al embarazo, o condiciones que pudieran alterar la HbA1c. Se midieron glicemia y HbA1c al ingreso, y curva de tolerancia a la glucosa (CTG) con 75 g semanas 24-28, y resultados perinatales y maternos al parto. Se hace análisis descriptivo y se presenta la prevalencia de DMG.Resultados: de un total de 372 gestantes candidatas a ingresar al estudio se detectaron dos casos (0,5 %) de diabetes mellitus previa al embarazo. De las 370 que cumplieron los criterios de selección, un total de 43 (11,6 %) presentaron aborto, otras 36 (9,7 %) se retiraron antes de la semana 24; de las 291 restantes, 35 (12 %) no se realizaron la CTG, por lo que se tomó la CTG en 256 gestantes, de las cuales se encontró CTG anormal en 12 casos, para una incidencia de DMG de 4,7 % (12/256).Conclusiones: la prevalencia de DMG fue del 4,7 % en la población estudiada, podría haber subestimación de la frecuencia por pérdidas antes de la semana 24. No se encontraron resultados perinatales adversos en este grupo de gestantes.

show abstract

Difficulties in interpreting HbA1c results

Cited by 13 publications

References 0 publications

Proteome‐base biomarkers in diabetes mellitus: Progress on biofluids' protein profiling using mass spectrometry

Proteome‐base biomarkers in diabetes mellitus: Progress on biofluids' protein profiling using mass spectrometry

Credibility of measurement of fructosamine and hemoglobin A1C in estimating blood glucose level of diabetic patients with thalassemia major

Prevalencia de Diabetes Mellitus Gestacional por curva de tolerancia a la glucosa en semanas 24 a 28. Cohorte prospectiva en Armenia Colombia, 2015-2016

Contact Info

Product

Resources

About